Research is underway on the development of a combination of probiotics (BEPC22, BELP53) related to fat and glucose metabolism in the body.
Using a mouse model with a high-fat diet, reductions in body weight and body fat were confirmed… Changes in obesity-related biomarkers appear
After human application tests, demand for individually approved functional raw materials for health functional foods and an alternative to curb obesity is expected.
Results of weight change of experimental mice administered a lactic acid bacteria formula for body fat reduction (Photo = Hecto Healthcare)
[바이오타임즈] Animal test results showing that a mixture of lactic acid bacteria (formula) suppresses obesity have been published in an international academic journal.
Healthcare IT company Hecto Healthcare has published research results showing that its self-developed lactic acid bacteria formula helps suppress obesity caused by a high-fat diet in the international academic journal Science and Technology Citation Index (SCI) “Food & Function”. Food and Function is recognized as an authority on food and nutrition, recording an Impact Factor (IF) of 6.1.
The research team (hereinafter referred to as the research team), consisting of Hecto Healthcare and academic experts, conducted the ‘L. Paracasei BEPC22’ (hereinafter BEPC22) and ‘L. A formula containing Plantarum BELP53 (hereinafter referred to as BELP53) was administered to experimental mice and a reduction in body fat was confirmed. BEPC22 and BELP53 used in the study affect fat and glucose metabolism in the body and are strains of lactic acid bacteria developed by Hecto Healthcare.
According to the results of the experiment, among mice in which obesity was induced with a high-fat diet, the group that received the formula for 10 weeks had significantly less weight gain than the group that ate only BEPC22 or BELP53 , and the one that ate only BEPC22 or BELP53. the size of the adipose tissue and the adipose cells that compose it had all decreased. Obesity is a condition in which excess fat accumulates due to an increase in the size or number of fat cells. A decrease in adipose tissue and cell size indicates a decrease in body fat.
Changes in obesity-related biomarkers were also confirmed. The expression of genes involved in fat production is decreased and the expression of genes related to lipolysis is increased, thus promoting fat burning. Furthermore, an increase in specific lipids in the stool was observed, resulting in a decrease in the absorption of specific lipids into the body.
Regarding these changes, the research team stated: “Due to the characteristics of each strain involved in fat and glucose metabolism and the action of the formula combining the two strains, the proportion of beneficial intestinal bacteria is increased and the body fat was reduced,” adding: “Lactobacillus is effective in suppressing obesity.” “It can be an alternative,” he said.
Hecto Healthcare has registered a patent for its in-house developed lactic acid bacteria and formula and plans to once again demonstrate body fat reduction through human application tests in the future and apply for approval as an individually recognized functional raw material for food functional for health.
[바이오타임즈=정민구 기자] news@biotimes.co.kr
Copyright © BioTimes. Reproduction and redistribution prohibited.
#Hecto #Healthcare #publishes #research #results #lactic #acid #bacteria #mixture #body #fat #reduction #journal #SCIlevel
